Sagittarius Life Science (3205) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Sagittarius Life Science TWD 10.04, price TWD 46.95, upside -78.6%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sagittarius Life Science for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products.
Show more
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Stock analysis
Sagittarius Life Science (3205) currently trades at 46.95 TWD, while our model-based Fair Value estimate is 10.04 TWD, implying the stock looks roughly 367.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 6.63 TWD (bear) to 12.56 TWD (bull), the price of 46.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Sagittarius Life Science reported revenue of 346M TWD in FY2025 versus 588M TWD in FY2021, a compound −12.4%/yr. Reported net income was −49.6M TWD in FY2025.
Key figures
Market cap 3.2B TWD (≈ $99.6M) · P/S ratio 8.68 · EPS (TTM) −0.9200 TWD · Net margin −14.3% · Return on equity −4.3% · Return on assets (EBIT) −10.4% · Operating margin 1.0% · Revenue (TTM) 392M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −79%, 3205 screens richer than that median.
Fair Value models
Bear 6.63 TWDFair Value 10.04 TWDBull 12.56 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−26.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.1%
Start year 2020 (pandemic). Over 10 years: −12.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.2% (2020) → −16.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Sagittarius Life Science with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−79% · Bottom 25%
Profitability
Return on assets−3% · Above median
Net margin (TTM)−8% · Below median
Operating margin (TTM)1% · Above median
Growth and dividend
Revenue growth46% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.10× · Cheapest 25%
P/S (TTM)0.27× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sagittarius Life Science Fair Value". https://www.fairvalue-calculator.com/stock/3205
Frequently asked questions
Is Sagittarius Life Science (3205) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10.04 TWD versus a price of 46.95 TWD, about −79% upside (overvalued).
What is the fair value of 3205?
Our model-based fair value for Sagittarius Life Science is 10.04 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 46.95 TWD.
What is the quality score of 3205?
Sagittarius Life Science has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sagittarius Life Science (3205)?
Our model-based price target is the fair value of 10.04 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 6.63 TWD, optimistic scenario 12.56 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sagittarius Life Science stock forecast for 2026?
Our models put fair value at 10.04 TWD, about −79% upside versus a price of 46.95 TWD (overvalued). Cautious scenario 6.63 TWD, optimistic scenario 12.56 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sagittarius Life Science (3205)?
Sagittarius Life Science reported trailing-twelve-month revenue of about 392M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Sagittarius Life Science (3205)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sagittarius Life Science it is 10.04 TWD per share (as of Sep 24, 2026), against a price of 46.95 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sagittarius Life Science stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 3205 trades above its calculated fair value: price 46.95 TWD, fair value 10.04 TWD, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3205?
No. The price is what the market pays today (46.95 TWD); the fair value is what the company's own numbers justify (10.04 TWD). For Sagittarius Life Science the two are 36.91 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sagittarius Life Science worth?
The market values Sagittarius Life Science at about 3.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 46.95 TWD; our models calculate a fair value of 10.04 TWD per share.
What do the bullish and bearish scenarios say about 3205?
Our models span a range for Sagittarius Life Science: cautious scenario 6.63 TWD, base 10.04 TWD, optimistic 12.56 TWD per share (as of Sep 24, 2026, price 46.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sagittarius Life Science (3205)?
Balance-sheet figures for Sagittarius Life Science (as of Sep 24, 2026): return on equity −4.3%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 3205 from its 52-week high?
Sagittarius Life Science trades at 46.95 TWD, about 25% below its 52-week high of 62.50 TWD and 7% above the low of 43.95 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 10.04 TWD is for.
Which stocks are comparable to Sagittarius Life Science?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sagittarius Life Science stock attractive at the current price?
The data as of Sep 24, 2026: price 46.95 TWD, calculated fair value 10.04 TWD (−79%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3205 calculated?
We run Sagittarius Life Science through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.04 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Sagittarius Life Science itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sagittarius Life Science (3205)?
The closing price on Sep 24, 2026 was 46.95 TWD. Our model-based fair value is 10.04 TWD, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sagittarius Life Science right now?
The price sits above even our optimistic bull case (12.56 TWD). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.63 TWD to 12.56 TWD) leaves room in how you read the outcome.
Key figures of Sagittarius Life Science
How large is the market capitalisation of Sagittarius Life Science (3205)?
The market capitalisation of Sagittarius Life Science is 3.2B TWD (≈ $99.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sagittarius Life Science (3205)?
The price-to-sales ratio of Sagittarius Life Science is 8.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sagittarius Life Science (3205)?
Earnings per share at Sagittarius Life Science are −0.9200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sagittarius Life Science (3205)?
The net margin of Sagittarius Life Science is −14.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sagittarius Life Science (3205)?
The return on equity (ROE) of Sagittarius Life Science is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sagittarius Life Science (3205)?
On an EBIT basis the return on assets of Sagittarius Life Science is −10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sagittarius Life Science (3205)?
The operating margin of Sagittarius Life Science is 1.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sagittarius Life Science (3205)?
Revenue at Sagittarius Life Science is growing +45.7% versus a year earlier (3y avg −13.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sagittarius Life Science (3205) generate?
The free cash flow of Sagittarius Life Science is −36.5M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sagittarius Life Science (3205) hold?
Sagittarius Life Science holds more cash than debt, 121M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sagittarius Life Science in the live analysis
One click puts Sagittarius Life Science on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
